PMID- 33088506
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 2050-0068 (Print)
IS  - 2050-0068 (Electronic)
IS  - 2050-0068 (Linking)
VI  - 9
IP  - 10
DP  - 2020
TI  - Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19).
PG  - e1198
LID - 10.1002/cti2.1198 [doi]
LID - e1198
AB  - Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand 
      healthy donors and one of the commonly used immunotherapeutic molecules for the 
      management of autoimmune and inflammatory diseases, has been explored for the 
      treatment of coronavirus disease-19 (COVID-19). Although placebo-controlled, 
      double-blind randomised clinical trials are lacking, current data from either 
      retrospective, case series or open-label randomised controlled trials provide an 
      indicator that IVIG immunotherapy could benefit severe and critically ill 
      COVID-19 patients. See alsoShao et al.
CI  - (c) 2020 The Authors. Clinical & Translational Immunology published by John Wiley & 
      Sons Australia, Ltd on behalf of Australian and New Zealand Society for 
      Immunology, Inc.
FAU - Galeotti, Caroline
AU  - Galeotti C
AD  - Service de Rhumatologie Pediatrique Centre de Reference des Maladies 
      Auto-Inflammatoires Rares et des Amyloses CHU de Bicetre le Kremlin Bicetre 
      France.
FAU - Kaveri, Srini V
AU  - Kaveri SV
AD  - Institut National de la Sante et de la Recherche Medicale Centre de Recherche des 
      Cordeliers Sorbonne Universite Universite de Paris Paris France.
FAU - Bayry, Jagadeesh
AU  - Bayry J
AUID- ORCID: 0000-0003-0498-9808
AD  - Institut National de la Sante et de la Recherche Medicale Centre de Recherche des 
      Cordeliers Sorbonne Universite Universite de Paris Paris France.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - Australia
TA  - Clin Transl Immunology
JT  - Clinical & translational immunology
JID - 101638268
PMC - PMC7565103
COIS- The authors declare no conflict of interest.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
PMCR- 2020/10/16
CRDT- 2020/10/22 05:37
PHST- 2020/09/27 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/22 05:37 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
PHST- 2020/10/16 00:00 [pmc-release]
AID - CTI21198 [pii]
AID - 10.1002/cti2.1198 [doi]
PST - epublish
SO  - Clin Transl Immunology. 2020 Oct 16;9(10):e1198. doi: 10.1002/cti2.1198. 
      eCollection 2020.